CureVac Shareholders Face Pivotal Acquisition Vote

Strategic Acquisition Reaches Critical Phase

The fate of CureVac hangs in the balance as shareholders approach a critical decision point regarding BioNTech’s acquisition proposal. With a tender offer now officially underway, investors must weigh a substantial share-exchange deal that would fundamentally reshape the mRNA biotechnology landscape.

BioNTech has formally initiated the exchange process, proposing that CureVac shareholders receive approximately $5.46 in BioNTech shares for each CureVac share they hold. This transaction, valued at $1.25 billion overall, represents a significant strategic pivot for both organizations. The deal has already garnered substantial support, with shareholders representing more than 50% of CureVac’s equity indicating their approval, including major investor dievini Hopp BioTech holding.